# A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer

> **NCT07198633** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 212 (estimated)

## Conditions studied

- Advanced Prostate Cancer

## Interventions

- **DRUG:** QLC5508
- **DRUG:** abiraterone acetate
- **DRUG:** enzalutamide
- **DRUG:** QLH12016

## Key facts

- **NCT ID:** NCT07198633
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-10
- **Primary completion:** 2026-12
- **Final completion:** 2027-12
- **Target enrollment:** 212 (ESTIMATED)
- **Last updated:** 2025-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07198633

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07198633, "A Clinical Study of QLC5508 and/or QLH12016 in Combination With Other Anti-tumor Therapies in Subjects With Advanced Prostate Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07198633. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*